

# Dissemination and Characteristics of High-Level Erythromycin-Resistant *Enterococcus Faecalis* From Bulk Tank Milk of Dairy Companies in Korea

Yu Jin Lee

Kyungpook National University

Koeun Kim

Kyungpook National University

Young Ju Lee (✉ [youngju@knu.ac.kr](mailto:youngju@knu.ac.kr))

Kyungpook National University

---

## Research Article

**Keywords:** high-level erythromycin-resistance, *Enterococcus faecalis*, milk, multidrug resistance

**Posted Date:** July 14th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-598748/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

# Abstract

**Background:** Enterococci are environmental pathogens that can cause bovine mastitis and macrolides are widely used for the treatment of bovine mastitis caused by staphylococci and streptococci/enterococci. The aim of this study was performed to compare the phenotypic and genotypic characteristics of high-level erythromycin-resistant (HLER) *Enterococcus faecalis* (*E. faecalis*) collected from bulk tank milk of four dairy companies (A, B, C, and D) in Korea.

**Results:** Although isolates from company D showed the highest prevalence of *E. faecalis*, the prevalence of HLER *E. faecalis* in company A (73.1%) and C (57.0%) was significantly higher than company D (33.9%) ( $P < 0.05$ ). A total of 149 HLER *E. faecalis* isolates showed high rates of resistance to tetracycline (93.3%), followed by doxycycline (70.0%), and chloramphenicol (48.3%). In the distribution of macrolides resistance genes, 147 (98.7%) isolates carried *ermB* gene alone, and two isolates carried both *ermA* and *ermB* genes. No isolates carried *ermC*, *msrA*, *msrC*, or *mef* genes. In the distribution of other resistance genes, 72 (48.3%) and 60 (40.3%) isolates carried both *tetM* and *tetL* genes, and *tetM* gene alone, respectively, and 38 (25.5%) isolates carried *optrA* gene. For aminoglycosides resistance genes, the prevalence of both *aac(6')Ie-aph(2'')-Ia* and *ant(6')-Ia* genes (43.0%) was the highest. Moreover, 104 (70.0%) isolates harbored *Int-Tn* gene carrying the *Tn916/1545*-like transposon. Although the distribution of *ermB* gene showed no significant difference between the dairy companies, the prevalence of other resistance genes and transposons showed a significant difference between the dairy companies ( $P < 0.05$ ). Virulence genes, such as *ace* (99.3%), *cad1* and *efaA* (each 98.7%), and *gelE* (83.9%), were also highly conserved in the 149 HLER *E. faecalis* isolates.

**Conclusions:** Our results indicated that HLER *E. faecalis* isolates from bulk tank milk showed significant differences in phenotypic and genotypic characteristics between the dairy companies. In addition, the prevalence of resistance genes and virulence factors was also high in HLER *E. faecalis* isolates.

## Background

Although enterococci are harmless commensal inhabitants of the gastrointestinal tract of humans and animals, they are most frequently implicated in human nosocomial infections [1, 2]. In food-producing livestock, enterococci may occur as a secondary infection in a variety of poultry diseases, and are considered environmental mastitis-causing pathogens in bovines [2, 3]. In particular, bovine mastitis is one of the most costly diseases because an antimicrobial approach should be the first option to inhibit pathogen growth in the mammary gland, although a major herd infection caused by enterococci is relatively rare [4].

Macrolides, including erythromycin (ERY), tylosin, and azithromycin, are potential inhibitors of protein synthesis that bind to the 50S subunits in the bacteria ribosomal 23S rRNA [5, 6], and are classified by the World Health Organization as “critically important in human medicine” [7]. However, in Korea, the usage of macrolides to livestock has constantly been increasing since 2016 and also increased by approximately 7% in 2019 compared with 2018 [8, 9].

Enterococci are intrinsically susceptible to ERY due to domain II and domain V of 23S rRNA [10–12], but resistance to ERY has been continuously reported due to acquired ERY resistance genes, such as *ermB* gene [6, 13]. In particular, Kim et al., (2012) [14] reported that enterococci from bovine milk in Korea showed the high resistance to ERY, and 97.4% of ERY-resistant enterococci possessed resistance genes. Moreover, Kim et al.,

(2018) [15] reported that enterococci could easily acquire resistance genes against many antimicrobials, and Chajęcka-Wierzchowska et al., (2019) [16] also reported that enterococci could possess highly effective gene transfer mechanisms, such as conjugative transposons. Thus, the aim of this study was performed to compare the phenotypic and genotypic characteristics of high-level ERY-resistant (HLER) *Enterococcus faecalis* (*E. faecalis*) isolates from bulk tank milk of dairy companies to assess its threat to public health.

## Results

### Distribution of HLER *E. faecalis* isolates and antimicrobial resistance

Comparative antimicrobial resistance of the 149 HLER *E. faecalis* isolates from bulk tank milk of four dairy companies is shown in Table 1. Although isolates from company D showed the highest prevalence of *E. faecalis*, the prevalence of HLER *E. faecalis* in company A (73.1%) and C (57.0%) was significantly higher than company D (33.9%) ( $P < 0.05$ ). All HLER *E. faecalis* isolates showed high rates of resistance to TET (93.3%), followed by DOX (70.0%), and CHL (48.3%). In particular, the resistance against these three antimicrobials showed significant differences between dairy companies ( $P < 0.05$ ). Resistance against AMP, CIP, PEN, RIF, and VAN was only 0.7–5.4% without significant differences between dairy companies.

Table 1  
Antimicrobial resistance of 149 high-level erythromycin-resistant *E. faecalis* from bulk tank milk in dairy companies

Company (No. of farms)	No. of <i>E. faecalis</i> <sup>1</sup>	No. (%) of HLER <sup>2</sup>	No. (%) of antimicrobial resistant HLER isolates by company <sup>3</sup>							
			AMP	CHL	CIP	DOX	PEN	RIF	TET	VAN
A (106)	52	38 (73.1) <sub>a</sub>	0 (0.0)	30 (78.9) <sub>a</sub>	0 (0.0)	27 (71.1) <sub>a,b</sub>	1 (2.6)	3 (7.9)	37 (97.4) <sub>a</sub>	0 (0.0)
B (47)	39	20 (51.3) <sub>a,b</sub>	1 (5.0)	13 (65.0) <sub>a,b</sub>	0 (0.0)	11 (55.0) <sub>b</sub>	0 (0.0)	0 (0.0)	15 (75.0) <sub>b</sub>	1 (5.0)
C (120)	86	49 (57.0) <sub>a</sub>	0 (0.0)	20 (41.0) <sub>b,c</sub>	2 (4.1)	29 (59.2) <sub>b</sub>	0 (0.0)	5 (10.2)	45 (91.8) <sub>a,b</sub>	0 (0.0)
D (123)	124	42 (33.9) <sub>b</sub>	0 (0.0)	9 (21.4) <sub>c</sub>	0 (0.0)	37 (88.1) <sub>a</sub>	0 (0.0)	0 (0.0)	42 (100.0) <sub>a</sub>	0 (0.0)
Total (396)	301	149 (49.5)	1 (0.7)	72 (48.3)	2 (1.4)	104 (70.0)	1 (0.7)	8 (5.4)	139 (93.3)	1 (0.7)

Values within a column not having the same small subscripts are significantly different ( $P < 0.05$ ).

<sup>1</sup>All *E. faecalis* were isolated from bulk tank milk samples collected each time in the summer and winter seasons by farms.

<sup>2</sup>HLEER, high-level erythromycin-resistance.

<sup>3</sup>Abbreviation: AMP, Ampicillin; CHL, Chloramphenicol; CIP, Ciprofloxacin; DOX, Doxycycline; PEN, Penicillin; RIF, Rifampin; TET, Tetracycline; VAN, Vancomycin.

## Distribution Of Mdr Patterns

The prevalence of MDR in the 149 HLEER *E. faecalis* isolates is shown in Fig. 1. Although the prevalence of MDR in HLEER *E. faecalis* showed no significant differences between dairy companies, HLEER *E. faecalis* isolates from company D showed the highest MDR (100.0%), followed by company A (92.1%), C (85.7%), and B (85.0%). All MDR isolates were resistant against three to five antimicrobial classes. Interestingly, HLEER *E. faecalis* isolates from company A (57.9%) and B (55.0%) showed significantly higher resistance against four antimicrobial classes, and isolates from company D (78.6%) showed the highest MDR against three classes ( $P < 0.05$ ). MDR against five classes was only observed in HLEER *E. faecalis* isolates from company A (7.9%) and C (10.2%).

## Distribution Of Antimicrobial Resistance Genes And Transposon Genes

Distribution of antimicrobial resistance genes and transposon genes

The distribution of resistance genes and transposons in the 149 HLEER *E. faecalis* isolates is shown in Table 2. In prevalence of macrolides resistance genes, 147 (98.7%) isolates carried *ermB* gene alone, and two isolates from company C carried both *ermA* and *ermB* genes. No isolates carried *ermC*, *msrA*, *msrC*, or *mef* genes. In the distribution of other resistance genes, 72 (48.3%) and 60 (40.3%) isolates carried both *tetM* and *tetL* genes, and *tetM* gene alone, respectively, which are related with tetracyclines resistance, and 38 (25.5%) isolates carried *optrA* gene, which is related with phenicols resistance. Of the aminoglycosides resistance genes, the prevalence of both *aac(6')Ie-aph(2'')-Ia* and *ant(6')-Ia* genes (43.0%) was the highest. Moreover, 104 (70.0%) isolates harbored *Int-Tn* gene carrying the *Tn916/1545*-like transposon. Although the distribution of *ermB* gene showed no significant differences between dairy companies, the prevalence of other resistance genes and transposons showed a significant difference between the dairy companies ( $P < 0.05$ ).

Table 2

Antimicrobial resistance genes in 149 high-level erythromycin-resistant *E. faecalis* from bulk tank milk in dairy companies

Antimicrobial resistance gene	No. (%) of isolates with antimicrobial resistance gene(s) by company <sup>1</sup>				
	A	B	C	D	Total
	(n = 38)*	(n = 20)	(n = 49)	(n = 42)	(n = 149)
Macrolides					
<i>ermA</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<i>ermB</i>	38 (100.0)	20 (100.0)	47 (95.9)	42 (100.0)	147 (98.7)
<i>ermC</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<i>ermA + ermB</i>	0 (0.0)	0 (0.0)	2 (4.1)	0 (0.0)	2 (1.3)
<i>msrA</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<i>msrC</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<i>mef</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Tetracyclines					
<i>tetL</i>	0 (0.0)	1 (5.0)	2 (4.1)	0 (0.0)	3 (2.0)
<i>tetM</i>	23 (60.5) <sub>a</sub>	2 (10.0) <sub>b</sub>	27 (55.1) <sub>a</sub>	8 (19.0) <sub>b</sub>	60 (40.3)
<i>tetO</i>	0 (0.0)	2 (10.0)	0 (0.0)	0 (0.0)	2 (1.3)
<i>tetL + tetM</i>	12 (31.6) <sub>b</sub>	10 (50.0) <sub>a,b</sub>	16 (32.7) <sub>b</sub>	34 (81.0) <sub>a</sub>	72 (48.3)
Phenicols					
<i>cfr</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<i>fexA</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<i>optrA</i>	17 (44.7) <sub>a</sub>	6 (30.0) <sub>a,b</sub>	10 (20.4) <sub>a,b</sub>	5 (11.9) <sub>b</sub>	38 (25.5)
Aminoglycosides					
<i>aac(6')Ie-aph(2'')-Ia</i>	2 (5.3)	1 (5.0)	4 (8.2)	1 (2.4)	8 (5.4)
<i>aph(2'')-Ib</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<i>aph(2'')-Ic</i>	0 (0.0)	1 (5.0)	1 (2.0)	0 (0.0)	2 (1.3)
<i>aph(2'')-Id</i>	0 (0.0)	0 (0.0)	0 (0.0)	3 (7.1)	3 (2.0)
<i>ant(3'')-Ia</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
<i>ant(6')-Ia</i>	6 (15.8)	6 (30.0)	11 (22.4)	4 (9.5)	27 (18.1)
<i>aac(6')Ie-aph(2'')-Ia + ant(6')-Ia</i>	11 (28.9) <sub>a,b</sub>	6 (30.0) <sub>b</sub>	18 (36.7) <sub>b</sub>	29 (69.0) <sub>a</sub>	64 (43.0)
<i>aph(2'')-Ic + ant(6')-Ia</i>	1 (2.6)	0 (0.0)	1 (2.0)	1 (2.4)	3 (2.0)

Antimicrobial resistance gene	No. (%) of isolates with antimicrobial resistance gene(s) by company <sup>1</sup>				
	A	B	C	D	Total
	(n = 38)*	(n = 20)	(n = 49)	(n = 42)	(n = 149)
<i>aph(2'')-IId + ant(6')-Ia</i>	1 (2.6)	2 (10.0)	3 (6.1)	0 (0.0)	6 (4.0)
<i>aph(2'')-Ic + aph(2'')-IId + ant(6')-Ia</i>	0 (0.0)	0 (0.0)	1 (2.0)	0 (0.0)	1 (0.7)
Transposon					
<i>Int-Tn</i>	26 (68.4) <sub>a,b</sub>	9 (45.0) <sub>b</sub>	31 (63.3) <sub>b</sub>	38 (90.5) <sub>a</sub>	104 (70.0)
<i>tndX</i>	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

\* n = No. of high-level erythromycin resistant *E. faecalis* isolated from bulk tank milk by company.

<sup>1</sup>Values within a row not having the same small subscripts are significantly different ( $P < 0.05$ ).

## Distribution Of Virulence Genes

The distribution of virulence genes in the 149 HLER *E. faecalis* isolates is shown in Table 3. The most prevalent virulence gene was *ace* (99.3%), followed by *cad1* and *efaA* (each 98.7%), *gelE* (83.9%), *asa1* (67.1%), *esp* (13.4%), and *cylA* (8.1%). In particular, the prevalence of *cylA*, *esp*, and *gelE* genes was significantly differences between dairy companies ( $P < 0.05$ ).

Table 3

Virulence genes in 149 high-level erythromycin-resistant *E. faecalis* from bulk tank milk in dairy companies

Company	No. (%) of isolates by company <sup>1</sup>						
	<i>ace</i>	<i>asa1</i>	<i>cad1</i>	<i>cylA</i>	<i>efaA</i>	<i>esp</i>	<i>gelE</i>
A (n = 38) *	38 (100.0)	27 (71.1)	38 (100.0)	6 (15.8) <sub>a</sub>	38 (100.0)	3 (7.9) <sub>a,b</sub>	33 (86.8) <sub>a,b</sub>
B (n = 20)	19 (95.0)	12 (60.0)	20 (100.0)	2 (10.0) <sub>a,b</sub>	18 (90.0)	2 (10.0) <sub>a,b</sub>	15 (75.0) <sub>b</sub>
C (n = 49)	49 (100.0)	30 (61.2)	48 (98.0)	4 (8.2) <sub>a,b</sub>	49 (100.0)	13 (26.5) <sub>a</sub>	35 (71.4) <sub>b</sub>
D (n = 42)	42 (100.0)	31 (73.8)	41 (97.6)	0 (0.0) <sub>b</sub>	42 (100.0)	2 (4.8) <sub>b</sub>	42 (100.0) <sub>a</sub>
Total (n = 149)	148 (99.3)	100 (67.1)	147 (98.7)	12 (8.1)	147 (98.7)	20 (13.4)	125 (83.9)
* n = No. of high-level erythromycin-resistant <i>E. faecalis</i> isolated from the dairy company.							
<sup>1</sup> Values within a column not having the same subscript letter differ significantly ( $P < 0.05$ ).							

## Discussion

Macrolides are one of the most commonly used clinically important antibiotics and have been used to treat infections by Gram-positive bacteria, including enterococci [17]. Additionally, they also widely used in food-producing livestock in Korea [9]. Although ERY, which is a first-generation macrolide, is rarely used by dairy companies because it is rapidly inactivated in the stomach due to its extreme acid sensitivity [18], tylosin, which is also one of the macrolides, has been continually used for the treatment of infections caused by staphylococci and streptococci/enterococci. However, pathogen resistance to ERY in food-producing livestock has been conferred by cross-resistance to macrolides, including tylosin [19].

In this study, 149 of the 301 *E. faecalis* isolates from bulk tank milk samples from four dairy companies revealed HLER, with an MIC  $\geq$  128  $\mu\text{g}/\text{mL}$  to ERY. Generally, two principal mechanisms of macrolides resistance have been identified: the methylation of bacteria ribosomal 23S rRNA encoded by a series of structurally related *erm* genes [6, 13], and an efflux pump system mediated by the membrane-bound protein encoded by the macrolide efflux genetic assembly (*mef*) [20] and macrolide- and streptogramin B-resistant (*msr*) genes [21]. In this study, all 149 HLER *E. faecalis* isolates carried *ermB* gene, and two isolates carried both *ermA* and *ermB* genes. Kim et al., (2012) [14] also reported that 97.1% of ERY-resistant *E. faecalis* isolates from bovine milk samples in Korea with an MIC  $\geq$  64  $\mu\text{g}/\text{mL}$  carried *ermB* gene. *ermB* gene is considered the most widespread macrolides resistance gene among enterococci isolated from food-producing animals [22, 23]. Moreover, enterococci showing high-level resistance against an MIC  $\geq$  64 or  $\geq$  128  $\mu\text{g}/\text{mL}$  to ERY has a strong possibility of carrying *ermB* gene.

Interestingly, 139 (93.3%) of 149 HLER *E. faecalis* isolates were resistant to TET, and 137 (98.6%) of the 139 TET-resistant isolates carried tetracycline resistance genes. Many researchers have reported that genes associated with ERY and TET resistance are easily transferred via conjugative transposons, such as those in the *Tn916/1545* and *Tn5397* families [13, 24, 25]. In this study, 132 (88.6%) isolates carried *tetM* gene, including the combination of both *tetL* and *tetM* genes. Moreover, *Int-Tn* gene, the *Tn916/1545*-like family, was also carried by 104 (70.0%) isolates. In particular, all HLER *E. faecalis* isolates from company D harbored both *ermB* and *tetM* genes, and 90.5% of isolates from company D also carried *Int-Tn* gene. Additionally, the dissemination of MDR *E. faecalis* isolates is expected to increase in company D in the future because target modification encoded by *ermB* gene can also confer cross-resistance to macrolide, lincosamide, and streptogramin B antimicrobials [19].

In this study, 72 (48.3%) isolates and 101 (67.8%) isolates carried *aac(6')Ie-aph(2'')-Ia* and *ant(6')-Ia* gene, respectively, and both *aac(6')Ie-aph(2'')-Ia* and *ant(6')-Ia* genes also showed in 64 (43.0%) of these isolates. The *aac(6')Ie-aph(2'')-Ia* and *ant(6')-Ia* gene, which are associated with plasmid-mediated aminoglycoside-modifying enzymes (AMEs), are responsible for resistance to gentamicin and streptomycin, respectively, in enterococci [26, 27], and this study results demonstrated that *erm*, *tet*, and AME genes are commonly disseminated in HLER *E. faecalis* isolates from bulk tank milk in Korea. In this study, 38 (25.5%) isolates carried the phenicols resistance gene, *optrA*, which encodes an ATP-binding cassette transporter [28] and no isolates carried *cftr* or *fexA* genes. Phenicols resistance genes in milk and dairy products have not been reported in Korea until now, therefore, the presence of *optrA* gene in *E. faecalis* isolates from bulk tank milk may significantly accelerate the emergence of novel MDR bacteria.

Virulence genes, such as *ace* (99.3%), *cad1* and *efaA* (each 98.7%), and *gelE* (83.9%) were also highly conserved in the 149 HLER *E. faecalis* isolates. Generally, possessed and expressed virulence factors cause a more severe infection than strains that lacking virulence factors [29, 30]. Moreover, virulence factors accompanied by

resistance genes are of pathogenic importance [29–31]. Therefore, the dissemination of virulence factors in bacteria from bulk tank milk can also lead to public health concern. Our results indicate that although HLER *E. faecalis* isolates from bulk tank milk showed significant differences in phenotypic and genotypic characteristics between dairy companies, there is a high prevalence of isolates that carry a variety of antimicrobial resistance genes and virulence factors. Therefore, a structured management protocol by dairy companies and constant monitoring are necessary to minimize public health hazards.

## Conclusion

In this comprehensive research on HLER *E. faecalis* from bulk tank milk of four dairy companies in Korea, the distribution of antimicrobial resistance and the phenotypic and genotypic characteristics of HLER *E. faecalis* showed a significant difference between the dairy companies. Therefore, our results indicate that a structured management protocol by companies and constant monitoring are necessary to minimize public health hazards.

## Methods

### HLER *E. faecalis* isolates

A total of 1,584 batches of bulk tank milk, which were sampled twice each in the summer and winter seasons, were collected from 396 dairy farms managed by four dairy companies in Korea. The isolation and identification of *Enterococcus* spp. were performed following the standard microbiological protocols published by the Ministry of Food and Drug Safety (Korea) [32]. Briefly, one mL of the milk sample was cultured in nine mL of buffered peptone water (BPW; BD Biosciences, San Jose, CA, USA). Then, the pre-enriched BPW was transferred to Enterococcosel broth (BD Biosciences) at a 1:10 ratio and streaked onto Enterococcosel agar (BD Biosciences) after incubation at 37°C for 18–24 h. *E. faecalis* isolates were finally confirmed using polymerase chain reaction (PCR) with a specific primer for *ddl* gene as previously described [33]. Although a total of 301 *E. faecalis* were isolated in this study, 149 HLER *E. faecalis* strains with a minimum inhibitory concentration (MIC)  $\geq$  128  $\mu\text{g}/\text{mL}$  against ERY by the standard agar dilution method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) as previously described [34, 35]. *E. faecalis* ATCC 29212 was used as a standard strain for the MIC tests.

## Antimicrobial Susceptibility Testing

Based on the Clinical and Laboratory Standards Institute (CLSI) guidelines [35], all HLER *E. faecalis* isolates were determined for antimicrobial resistance using the disk diffusion method against eight antimicrobial agents (BD Bioscience, Sparks, MD, USA): ampicillin (AMP, 10  $\mu\text{g}$ ), chloramphenicol (CHL, 30  $\mu\text{g}$ ), ciprofloxacin (CIP, 5  $\mu\text{g}$ ), doxycycline (DOX, 30  $\mu\text{g}$ ), penicillin (PEN, 10 units), rifampin (RIF, 5  $\mu\text{g}$ ), tetracycline (TET, 30  $\mu\text{g}$ ), and vancomycin (VAN, 30  $\mu\text{g}$ ). Multidrug resistance (MDR) was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial classes [36].

## Detection Of Antimicrobial Resistance Genes, Transposons, And Virulence Genes

DNA extraction was prepared by boiling, as described previously [37]. The presence of resistance genes to macrolides (*ermA*, *ermB*, *ermC*, *msrA*, *msrC*, and *mef*), tetracyclines (*tetL*, *tetM*, and *tetO*), phenicols (*cfp*, *fexA*, and *optrA*), and aminoglycosides [*aac(6')Ie-aph(2'')-Ia*, *aph(2'')-Ib*, *aph(2'')-Ic*, *aph(2'')-Id*, *ant(3'')-Ia*, and *ant(6')-Ia*] was detected using PCR as described previously [38–46]. Additionally, *Tn916/1545*-like (*Int-Tn*) and *Tn5397*-like (*tndX*) transposons and virulence genes, such as *ace* (collagen-binding protein), *asa1* (aggregation substance), *cad1* (pheromone cAD1 precursor lipoprotein), *cytA* (cytolysin activator), *efaA* (cell wall-associated protein involved in immune evasion), *esp* (enterococcal surface protein), and *gelE* (gelatinase), were also determined by PCR as described previously [24, 47–49]. All PCR primers are listed in Table 4.

Table 4  
Primers used in this study

Description	Target gene	Primer sequence (5'→3')	Size (bp)	References
<i>E. faecalis</i> gene	<i>ddl1</i>	F: ATCAAGTACAGTTAGTCT R: ACGATTCAAAGCTAACTG	941	Dutka-Malen et al., 1995
Macrolides resistant gene	<i>ermA</i>	F: TAACATCAGTACGGATATTG	200	Di Cesare et al., 2013
		R: AGTCTACACTTGGCTTAGG		
	<i>ermB</i>	F: CCGAACACTAGGGTTGCTC	139	Di Cesare et al., 2013
		R: ATCTGGAACATCTGTGGTATG		
	<i>ermC</i>	F: TCAAAACATAATATAGATAAA	642	Sutcliffe et al., 1996
		R: GCTAATATTGTTTAAATCGTCAAT		
	<i>msrA</i>	F: GCAAATGGTGTAGGTAAGACAAC	402	Singh KV et al., 2001
		R: ATCATGTGATGTAAACAAAAT		
<i>msrC</i>	F: GCAAATGGTGTAGGTAAGACAAC	399	Sutcliffe et al., 1996 Singh KV et al., 2001	
	R: ATCATGTGATGTAAACAAAAT			
<i>mef</i>	F: AGTATCATTAACTACTAGTGC	348	Di Cesare et al., 2013	
	R: TTCTTCTGGTACTAAAAGTGG			
Tetracyclines resistant gene	<i>tetL</i>	F: TCGTTAGCGTGCTGTCATTC	267	Aarestrup et al., 2000
		R: GTATCCCACCAATGTAGCCG		
	<i>tetM</i>	F: GTGGACAAAGGTACAACGAG R: CGGTAAAGTTCGTCACACAC	406	Aarestrup et al., 2000
<i>tetO</i>	F: AACTTAGGCATTCTGGCTCAC	515	Aarestrup et al., 2000	
	R: TCCCACTGTTCCATATCGTCA			
Phenicols resistant gene	<i>cfr</i>	F: TGAAGTATAAAGCAGGTTGGGAGTCA	746	Kehrenberg and Schwarz, 2006
		R: ACCATATAATTGACCACAAGCAGC		
	<i>fexA</i>	F: GTACTTGTAGGTGCAATTACGGCTGA	1272	Kehrenberg and Schwarz, 2006
R: CGCATCTGAGTAGGACATAGCGTC				
<i>optrA</i>	F: AGGTGGTCAGCGAACTAA	1395	Wang et al., 2015	
	R: ATCAACTGTTCCCATTC			
Aminoglycosides resistant gene	<i>aac(6')Ie-aph(2'')-Ia</i>	F: CAGAGCCTTGGGAAGATGAAG	348	Vakulenko et al., 2003

Description	Target gene	Primer sequence (5'→3')	Size (bp)	References
		R: CCTCGTGTAATTCATGTTCTGGC		
	<i>aph(2'')-Ib</i>	F: CTTGGACGCTGAGATATATGAGCAC R: GTTTGTAGCAATTCAGAAACACCCTT	867	Vakulenko et al., 2003
	<i>aph(2'')-Ic</i>	F: CCACAATGATAATGACTCAGTTCCC R: CCACAGCTTCCGATAGCAAGAG	444	Vakulenko et al., 2003
	<i>aph(2'')-Id</i>	F: GTGGTTTTTACAGGAATGCCATC R: CCCTCTTCATACCAATCCATATAACC	641	Vakulenko et al., 2003
	<i>ant(3'')-Ia</i>	F: TGATTTGCTGGTTACGGTGAC R: CGCTATGTTCTCTTGCTTTTG	284	Clark et al., 1999
	<i>ant(6'')-Ia</i>	F: ACTGGCTTAATCAATTTGGG R: GCCTTTCCGCCACCTCACCG	577	Sepúlveda A. et al., 2007
Transposon	<i>Int-Tn</i>	F: GCGTGATTGTATCTCACT R: GACGCTCCTGTTGCTTCT	1028	Doherty et al., 2000
	<i>tndX</i>	F: ATGATGGGTTGGACAAAGA R: CTTTGCTCGATAGGCTCTA	610	AgersΦ et al., 2006
Virulence gene	<i>ace</i>	F: GGAATGACCGAGAACGATGGC R: GCTTGATGTTGGCCTGCTTCCG	616	Billström et al., 2008
	<i>asa1</i>	F: CACGCTATTACGAACTATGA R: TAAGAAAGAACATCACCACGA	375	Billström et al., 2008
	<i>cad1</i>	F: TTCCAAAACACTACGCACAACA R: CTTTTTCAGCAGCATTCACTAATT	423	Song et al., 2019
	<i>cylA</i>	F: GACTCGGGGATTGATAGGC R: GCTGCTAAAGCTGCGCTTAC	688	Billström et al., 2008
	<i>efaA</i>	F: CGTGAGAAAGAAATGGAGGA R: CTAATAACACGTACGAATG	499	Billström et al., 2008
	<i>esp</i>	F: AGATTTTCATCTTTGATTCTTG R: AATTGATTCTTTAGCATCTGG	510	Billström et al., 2008
	<i>gelE</i>	F: TATGACAATGCTTTTTGGGAT	213	Billström et al., 2008

Description	Target gene	Primer sequence (5'→3')	Size (bp)	References
		R: AGATGCACCCGAAATAATATA		

## Statistical analysis

Statistical analysis by Pearson's chi-square tests and Fisher's exact tests with Bonferroni correction was performed using Statistical Package for the Social Science version 25 (SPSS; IBM, Korea). Significant differences were considered at  $P < 0.05$ .

## List Of Abbreviations

AMP: Ampicillin, CHL: Chloramphenicol, CIP: Ciprofloxacin, CLSI: Clinical and Laboratory Standards Institute, DOX: doxycycline, ERY: Erythromycin, *E. faecalis*: *Enterococcus faecalis*, HLER: High-Level Erythromycin-Resistant, MDR: Multi – drug resistance, PEN: Penicillin, RIF: Rifampin, TET: Tetracycline, VAN: Vancomycin, WHO: World Health Organization

## Declarations

### Ethics approval and consent to participate

Not applicable

### Consent for publication

Not applicable

### Availability of data and materials

The complete data sets used during the current study are available from the corresponding author on reasonable request.

### Competing interests

The authors declare that they have no competing interests.

### Funding

There was no financial support for this research.

### Authors' contributions

Conceptualization, Y.J. and Y.J.L.; methodology, Y.J., K.K and Y.J.L.; validation, Y.J., K.K. and Y.J.L.; formal analysis, Y.J. and K.K.; investigation, Y.J.; resources, Y.J. and Y.J.L.; data curation, Y.J. and K.K.; writing – original draft preparation, Y.J.; writing – review and editing, Y.J. and Y.J.L; visualization, Y.J.; supervision, Y.J.L.; project administration, Y.J.L. All authors have read and agreed to the published version of the manuscript.

## Acknowledgements

Not applicable

## References


1. Bittencourt De Marques E, Suzart S. Occurrence of virulence-associated genes in clinical *Enterococcus faecalis* strains isolated in Londrina, Brazil. *J Med Microbiol.* 2004;53:1069–73.
2. Woźniak-Biel A, Bugla-Płoskońska G, Burdzy J, Korzekwa K, Ploch S, Wieliczko A. Antimicrobial resistance and biofilm formation in *Enterococcus* spp. Isolated from humans and turkeys in Poland. *Microb Drug Resist.* 2019;25:277–86.
3. Elhadidy M, Elsayyad A. Uncommitted role of enterococcal surface protein, Esp, and origin of isolates on biofilm production by *Enterococcus faecalis* isolated from bovine mastitis. *J Microbiol Immunol Infect.* 2013;46:80–4. doi:10.1016/j.jmii.2012.02.002.
4. Mushtaq S, Shah AM, Shah A, Lone SA, Hussain A, Hassan QP, et al. Bovine mastitis: An appraisal of its alternative herbal cure. *Microb Pathog.* 2018;114:357–61. doi:10.1016/j.micpath.2017.12.024.
5. Allen NE. Macrolide resistance in *Staphylococcus aureus*: induction of macrolide resistant protein synthesis. *Antimicrob Agents Chemother.* 1977;11:661–8.
6. Portillo A, Ruiz-Larrea F, Zarazaga M, Alonso A, Martinez JL, Torres C. Macrolide resistance genes in *Enterococcus* spp. *Antimicrob Agents Chemother.* 2000;44:967–71.
7. World Health Organization. Critically Important Antimicrobials for human medicine, 6th revision. 2019. <https://www.who.int/foodsafety/publications/antimicrobials-sixth/en/>.
8. The Ministry of Food and Drug safety. National antimicrobial use and immunity monitoring. 2016. [https://www.mfds.go.kr/brd/m\\_231/view.do?seq=28155](https://www.mfds.go.kr/brd/m_231/view.do?seq=28155).
9. The Ministry of Food and Drug Safety. National antimicrobial use and immunity monitoring. 2019. [https://www.mfds.go.kr/brd/m\\_231/view.do?seq=33047](https://www.mfds.go.kr/brd/m_231/view.do?seq=33047).
10. Douthwaite S, Prince JB, Noller HF. Evidence for functional interaction between domains II and V of 23S ribosomal RNA from an erythromycin-resistant mutant. *Proc Natl Acad Sci U S A.* 1985;82:8330–4.
11. Xiong L, Shah S, Mauvais P, Mankin AS. A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. *Mol Microbiol.* 1999;31:633–9.
12. García-Solache M, Rice LB. The enterococcus: A model of adaptability to its environment. *Clin Microbiol Rev.* 2019;32:e00058-18.
13. Kim Y Bin, Seo KW, Jeon HY, Lim SK, Sung HW, Lee YJ. Molecular characterization of erythromycin and tetracycline-resistant *Enterococcus faecalis* isolated from retail chicken meats. *Poult Sci.* 2019;98:977–83. doi:10.3382/ps/pey477.
14. Kim J, Lee S, Choi S. Copper resistance and its relationship to erythromycin resistance in *Enterococcus* isolates from bovine milk samples in Korea. *J Microbiol.* 2012;50:540–3.
15. Kim YJ, Park JH, Seo KH. Comparison of the loads and antibiotic-resistance profiles of *Enterococcus* species from conventional and organic chicken carcasses in South Korea. *Poult Sci.* 2018;97:271–8. doi:10.3382/ps/pex275.

16. Chajęcka-Wierzchowska W, Zadernowska A, Zarzecka U, Zakrzewski A, Gajewska J. Enterococci from ready-to-eat food – horizontal gene transfer of antibiotic resistance genes and genotypic characterization by PCR melting profile. *Journal of the Science of Food and Agriculture*. 2019;99:1172–9.
17. Wang Y, Xiong Y, Wang Z, Zheng J, Xu G, Deng Q, et al. Comparison of solithromycin with erythromycin in *Enterococcus faecalis* and *Enterococcus faecium* from China: antibacterial activity, clonality, resistance mechanism, and inhibition of biofilm formation. *J Antibiot (Tokyo)*. 2021;74:143–51. doi:10.1038/s41429-020-00374-2.
18. Hassanzadeh A, Barber J, Morris GA, Gorry PA. Mechanism for the degradation of erythromycin A and erythromycin A 2'-ethyl succinate in acidic aqueous solution. *J Phys Chem A*. 2007;111:10098–104.
19. Jackson CR, Fedorka-Cray PJ, Barrett JB, Ladely SR. Effects of tylosin use on erythromycin resistance in enterococci isolated from swine. *Appl Environ Microbiol*. 2004;70:4205–10.
20. Cai Y, Kong F, Gilbert GL. Three new macrolide efflux (mef) gene variants in *Streptococcus agalactiae* [2]. *J Clin Microbiol*. 2007;45:2754–5.
21. Reynolds E, Ross JI, Cove JH. Msr(A) and related macrolide/streptogramin resistance determinants: Incomplete transporters? *Int J Antimicrob Agents*. 2003;22:228–36.
22. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. *Antimicrob Agents Chemother*. 1999;43:2823–30.
23. Okitsu N, Kaieda S, Yano H, Nakano R, Hosaka Y, Okamoto R, et al. Characterization of ermB gene transposition by Tn1545 and Tn917 in macrolide-resistant *Streptococcus pneumoniae* isolates. *J Clin Microbiol*. 2005;43:168–73.
24. Agersø Y, Pedersen AG, Aarestrup FM. Identification of Tn5397-like and Tn916-like transposons and diversity of the tetracycline resistance gene tet(M) in enterococci from humans, pigs and poultry. *J Antimicrob Chemother*. 2006;57:832–9.
25. Choi JM, Woo GJ. Transfer of Tetracycline Resistance Genes with Aggregation Substance in Food-Borne *Enterococcus faecalis*. *Curr Microbiol*. 2015;70:476–84.
26. Ounissi H, Derlot E, Carlier C, Courvalin P. Gene homogeneity for aminoglycoside-modifying enzymes in gram-positive cocci. *Antimicrob Agents Chemother*. 1990;34:2164–8.
27. Kim Y Bin, Seo KW, Son SH, Noh EB, Lee YJ. Genetic characterization of high-level aminoglycoside-resistant *Enterococcus faecalis* and *Enterococcus faecium* isolated from retail chicken meat. *Poult Sci*. 2019;98:5981–8. doi:10.3382/ps/pez403.
28. Hao W, Shan X, Li D, Schwarz S, Zhang SM, Li XS, et al. Analysis of a poxA- And oprA-co-carrying conjugative multiresistance plasmid from *Enterococcus faecalis*. *J Antimicrob Chemother*. 2019;74:1771–5.
29. Chajęcka-Wierzchowska W, Zadernowska A, Łaniewska-Trokenheim Ł. Virulence factors of *Enterococcus* spp. presented in food. *LWT - Food Sci Technol*. 2017;75:670–6.
30. Heidari H, Emaneini M, Dabiri H, Jabalameli F. Virulence factors, antimicrobial resistance pattern and molecular analysis of *Enterococcal* strains isolated from burn patients. *Microb Pathog*. 2016;90:93–7. doi:10.1016/j.micpath.2015.11.017.
31. Pillay S, Zishiri OT, Adeleke MA. Prevalence of virulence genes in enterococcus species isolated from companion animals and livestock. *Onderstepoort J Vet Res*. 2018;85:e1-8.

32. Ministry of Food and Drug Safety (MFDS). Processing Standards and Ingredient Specifications for Livestock Products; NIFDS.
33. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. *J Clin Microbiol.* 1995;33:1434.
34. Reyes J, Hidalgo M, Díaz L, Rincón S, Moreno J, Vanegas N, et al. Characterization of macrolide resistance in Gram-positive cocci from Colombian hospitals: a countrywide surveillance. *Int J Infect Dis.* 2007;11:329–36.
35. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 28th informational supplement. Wayne PA, USA: CLSI; 2018.
36. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012;18:268–81. doi:10.1111/j.1469-0691.2011.03570.x.
37. Bakshi CS, Shah DH, Verma R, Singh RK, Malik M. Rapid differentiation of *Mycobacterium bovis* and *Mycobacterium tuberculosis* based on a 12.7-kb fragment by a single tube multiplex-PCR. *Vet Microbiol.* 2005;109:211–6.
38. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. *Antimicrob Agents Chemother.* 1996;40:2562–6.
39. Clark NC, Olsvik Ø, Swenson JM, Spiegel CA, Tenover FC. Detection of a streptomycin/spectinomycin adenyltransferase gene (*aadA*) in *Enterococcus faecalis*. *Antimicrob Agents Chemother.* 1999;43:157–60.
40. Aarestrup FM, Agerso Y, Gerner-Smidt P, Madsen M, Jensen LB. Comparison of antimicrobial resistance phenotypes and resistance genes in *Enterococcus faecalis* and *Enterococcus faecium* from humans in the community, broilers, and pigs in Denmark. *Diagn Microbiol Infect Dis.* 2000;37:127–37.
41. Singh K V, Malathum K, Murray BE. Disruption of an *Enterococcus faecium* species-specific gene, a homologue of acquired macrolide resistance genes of staphylococci, is associated with an increase in macrolide susceptibility. *Antimicrob Agents Chemother.* 2001;45:263–6.
42. Vakulenko SB, Susan M. Donabedian AMV, Zervos MJ, Lerner SA, Chow JW. Multiplex PCR for detection of aminoglycoside resistance genes in enterococci. *Antimicrob Agents Chemother.* 2003;47:1423–6. doi:10.1128/AAC.47.4.1423-1426.2003.
43. Kehrenberg C, Schwarz S. Distribution of florfenicol resistance genes *fexA* and *cfr* among chloramphenicol-resistant *Staphylococcus* isolates. *Antimicrob Agents Chemother.* 2006;50:1156–63.
44. Sepúlveda A M, Bello T H, Domínguez Y M, Mella M S, Zemelman Z R, González R G. Molecular identification of aminoglycoside-modifying enzymes among strains of *Enterococcus* spp. isolated in hospitals of the VIII Region of Chile. *Rev Med Chil.* 2007;135:566–72.
45. Di Cesare A, Luna GM, Vignaroli C, Pasquaroli S, Tota S, Paroncini P, et al. Aquaculture Can Promote the Presence and Spread of Antibiotic-Resistant Enterococci in Marine Sediments. *PLoS One.* 2013;8:e62838.
46. Wang Y, Lv Y, Cai J, Schwarz S, Cui L, Hu Z, et al. A novel gene, *optrA*, that confers transferable resistance to oxazolidinones and phenicols and its presence in *Enterococcus faecalis* and *Enterococcus faecium* of human and animal origin. *J Antimicrob Chemother.* 2015;70:2182–90.
47. Doherty N, Trzcinski K, Pickerill P, Zawadzki P, Dowson CG. Genetic diversity of the *tet(M)* gene in tetracycline-resistant clonal lineages of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 2000;44:2979–84.

48. Billström H, Lund B, Sullivan Å, Nord CE. Virulence and antimicrobial resistance in clinical *Enterococcus faecium*. *Int J Antimicrob Agents*. 2008;32:374–7.
49. Song H, Bae Y, Jeon E, Kwon Y, Joh S. Multiplex PCR analysis of virulence genes and their influence on antibiotic resistance in *Enterococcus* spp. isolated from broiler chicken. *J Vet Sci*. 2019;20:e26.

## Figures



**Figure 1**

Distribution of multidrug resistant 149 high-level erythromycin-resistant *E. faecalis* from bulk tank milk in dairy companies. Values not having the same subscript letter differ significantly by company ( $P < 0.05$ ).